MA32764B1 - Inhibiteurs de l'intégrase du vih - Google Patents

Inhibiteurs de l'intégrase du vih

Info

Publication number
MA32764B1
MA32764B1 MA33804A MA33804A MA32764B1 MA 32764 B1 MA32764 B1 MA 32764B1 MA 33804 A MA33804 A MA 33804A MA 33804 A MA33804 A MA 33804A MA 32764 B1 MA32764 B1 MA 32764B1
Authority
MA
Morocco
Prior art keywords
hiv
compounds
inhibitors
antigrade
prophylaxis
Prior art date
Application number
MA33804A
Other languages
Arabic (ar)
English (en)
Inventor
Richard C A Isaacs
Wayne J Thompson
Peter D Williams
Dai-Shi Su
Shankar Venkatraman
Mark W Embrey
Thorsten E Fisher
John S Wai
David C Dubost
Richard G Ball
Eric J Choi
Tao Pei
Sarah L Trice
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32764B1 publication Critical patent/MA32764B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) QUI SONT DES INHIBITEURS DE L'INTÉGRASE DU VIH ET DES INHIBITEURS DE LA RÉPLICATION DU VIH. DANS LA FORMULE (I), X1, X2, Y, R1A, R1B, R2 ET R3 SONT DÉFINIS DANS LA DESCRIPTION. CES COMPOSÉS SONT UTILES DANS LA PROPHYLAXIE OU LE TRAITEMENT D'UNE INFECTION PROVOQUÉE PAR LE VIH ET LA PROPHYLAXIE, LE TRAITEMENT OU LE RETARDEMENT DU DÉCLENCHEMENT OU DE LA PROGRESSION DU SIDA. LES COMPOSÉS SELON L'INVENTION SONT UTILISÉS POUR LUTTER CONTRE UNE INFECTION VIH ET LE SIDA SOUS FORME DESDITS COMPOSÉS EUX-MÊMES (OU D'HYDRATES OU DE SOLVATES DE CEUX-CI) OU DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. CES COMPOSÉS ET LEURS SELS PEUVENT ÊTRE EMPLOYÉS EN TANT QU'INGRÉDIENTS DANS DES COMPOSITIONS PHARMACEUTIQUES, ÉVENTUELLEMENT COMBINÉS À D'AUTRES ANTIVIRAUX, IMMUNOMODULATEURS, ANTIBIOTIQUES OR VACCINS.
MA33804A 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih MA32764B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19527108P 2008-10-06 2008-10-06
PCT/US2009/059306 WO2010042391A2 (fr) 2008-10-06 2009-10-02 Inhibiteurs de l'intégrase du vih

Publications (1)

Publication Number Publication Date
MA32764B1 true MA32764B1 (fr) 2011-11-01

Family

ID=41682332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33804A MA32764B1 (fr) 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih

Country Status (22)

Country Link
US (2) US8513234B2 (fr)
EP (1) EP2349276B1 (fr)
JP (2) JP4880097B1 (fr)
KR (1) KR20110066224A (fr)
CN (1) CN102239172A (fr)
AR (1) AR073769A1 (fr)
AU (1) AU2009302663B2 (fr)
BR (1) BRPI0920605A8 (fr)
CA (1) CA2738814C (fr)
CO (1) CO6382127A2 (fr)
CR (1) CR20110184A (fr)
DO (1) DOP2011000093A (fr)
EA (1) EA201170537A1 (fr)
EC (1) ECSP11010959A (fr)
IL (1) IL212019A0 (fr)
MA (1) MA32764B1 (fr)
MX (1) MX2011003637A (fr)
NI (1) NI201100069A (fr)
PE (1) PE20110344A1 (fr)
TW (1) TW201020251A (fr)
WO (2) WO2010042391A2 (fr)
ZA (1) ZA201102620B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2014008636A1 (fr) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Composés macrocycliques en tant qu'inhibiteurs de l'intégrase du vih
CN102936188B (zh) * 2012-11-19 2015-07-15 湖北吉和昌化工科技有限公司 一种丙炔醇缩水甘油醚的合成方法
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
CN107722106A (zh) * 2016-08-11 2018-02-23 重庆大学 Hiv抑制剂
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
IL161337A0 (en) 2001-10-26 2004-09-27 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1467970B1 (fr) 2002-01-17 2007-08-22 Merck & Co., Inc. Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
NZ540729A (en) 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
WO2004062613A2 (fr) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Inhibiteurs d'integrase hiv
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
RU2006138864A (ru) 2004-04-06 2008-05-20 Чирон Корпорейшн (Us) Ингибиторы митотического кинезина
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (fr) * 2004-11-23 2006-06-08 Merck & Co., Inc. Processus destine a la synthese asymetrique d'hexahydropyrimido[1,2-a] azepine-2-carboxamides et de composes correspondants
CA2600832C (fr) * 2005-03-31 2011-12-13 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de l'integrase du vih
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007058646A1 (fr) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Inhibiteurs d’integrase du vih : composes cycliques de la pyrimidinone
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (fr) 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Heterocycles bicycliques en tant qu'inhibiteurs de l'integrase du vih
WO2007143446A1 (fr) 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Composés hétérotricycliques spiro-condensés utilisés en tant qu'inhibiteurs de la vih intégrase
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors

Also Published As

Publication number Publication date
US8513234B2 (en) 2013-08-20
US20100087419A1 (en) 2010-04-08
US20130338141A1 (en) 2013-12-19
IL212019A0 (en) 2011-06-30
BRPI0920605A2 (pt) 2015-12-22
CO6382127A2 (es) 2012-02-15
WO2010042392A2 (fr) 2010-04-15
WO2010042392A3 (fr) 2010-06-03
JP2012036207A (ja) 2012-02-23
AU2009302663A1 (en) 2010-04-15
AR073769A1 (es) 2010-12-01
ECSP11010959A (es) 2011-05-31
EP2349276A2 (fr) 2011-08-03
BRPI0920605A8 (pt) 2016-04-26
CN102239172A (zh) 2011-11-09
CA2738814A1 (fr) 2010-04-15
CA2738814C (fr) 2014-01-28
WO2010042391A3 (fr) 2010-06-03
ZA201102620B (en) 2011-12-28
DOP2011000093A (es) 2011-07-15
JP2012504648A (ja) 2012-02-23
NI201100069A (es) 2012-08-08
JP5600311B2 (ja) 2014-10-01
AU2009302663B2 (en) 2012-11-08
KR20110066224A (ko) 2011-06-16
WO2010042391A2 (fr) 2010-04-15
EA201170537A1 (ru) 2011-12-30
MX2011003637A (es) 2011-04-27
EP2349276B1 (fr) 2019-11-27
TW201020251A (en) 2010-06-01
JP4880097B1 (ja) 2012-02-22
CR20110184A (es) 2011-06-08
PE20110344A1 (es) 2011-06-22

Similar Documents

Publication Publication Date Title
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA29745B1 (fr) Inhibiteurs de la transcriptase inverse du vih
TN2011000316A1 (fr) Derives de sulfonamides
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA31754B1 (fr) Cis-imidazolines chirales
TN2009000450A1 (fr) Derives de pyridine
MA42292A (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
TNSN07022A1 (fr) Derives de pyridine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
WO2009146555A8 (fr) Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
TNSN08139A1 (fr) Composes therapeutiques
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
WO2005086700A3 (fr) Inhibiteurs de l'integrase du vih
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique